Biosimilars advancements: Moving on to the future

Biotechnology Progress

Volumn 31, Issue 5, 2015, Pages 1139-1149

  Tsuruta, Lilian Rumi ^a   Lopes dos Santos, Mariana ^a   Moro, Ana Maria ^a,b  

^a INSTITUTO BUTANTAN   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Bioassays; Biosimilars; Comparability; High order structure; Monoclonal antibodies

Indexed keywords

BIOASSAY; BIOLOGY; COMMERCE; MANUFACTURE; MONOCLONAL ANTIBODIES;

BIOLOGICAL CHARACTERIZATION; BIOSIMILARS; COMPARABILITY; HIGH-ORDER STRUCTURE; MANUFACTURING PROCESS; MONOCLONAL ANTIBODIES (MABS); PHARMACEUTICAL INDUSTRY; TECHNOLOGICAL CHALLENGES;

PRODUCT DESIGN;

BIOSIMILAR AGENT;

ANIMAL; BIOTECHNOLOGY; DISEASE MODEL; DRUG INDUSTRY; ECONOMICS; HUMAN; TRENDS;

ANIMALS; BIOSIMILAR PHARMACEUTICALS; BIOTECHNOLOGY; DISEASE MODELS, ANIMAL; DRUG INDUSTRY; HUMANS;

EID: 84944880087     PISSN: 87567938     EISSN: 15206033     Source Type: Journal    
DOI: 10.1002/btpr.2066     Document Type: Article

References (105)

1. Johnson IS. Human insulin from recombinant DNA technology. Science. 1983;219:632-637.
2. Tsiftsoglou AS, Ruiz S, Schneider CK. Development and regulation of biosimilars: current status and future challenges. BioDrugs. 2013;27:203-211.
3. Aagaard AW, Purdy S, Philpott S. Review, approval, and marketing of biosimilars in the United States. BioProcess Int. 2010;8:12-20.
4. EMA/CHMP/437/04 Rev 1. Guideline on Similar Biological Medicinal Products. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2014/10/WC500176768.pdf. April, 2015. Accessed March 4, 2015.
5. EMA/CHMP/BMWP/42832/2005. Guideline on Similar Biological Medicinal Products Containing Biotechnology-Derived Proteins as Active Substance: Non-Clinical and Clinical Issues. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003920.pdf. June, 2006. Accessed March 4, 2015.
6. Biologics Price Competition and Innovation Act of 2009. Section 7002(a)(2)(k)(2)(A)(i)(I)(cc). Available at: www.govtrack.us/congress/bill.xpd?bill=h111-3590. September, 2009. Accessed December 22, 2014.
7. van Aerts LA, De Smet K, Reichmann G, Willem van der Laan J, Schneider CK. Biosimilars entering the clinic without animal studies: a paradigm shift in the European Union. mAbs. 2014;6:1155-1162.
8. EMA. European public assessment reports (EPAR) for human medicines. Available at: http://www.ema.europa.eu/ema/index.jsp?curl=pages%2Fmedicines%2Flanding%2Fepar_search.jsp&mid=WC0b01ac058001d124&searchTab=searchByAuthType&alreadyLoaded=true&isNewQuery=true&status=Authorised&status=Withdrawn&status=Suspended&status=Refused&keyword=Enter+keywords&searchType=name&taxonomyPath=&treeNumber=&searchGenericType=biosimilars. 2014. Accessed November 12, 2014.
9. Weinstein V. Looking at the Recent FDA Biosimilar Guidelines. BioProcess Int. 2012;10:10-14.
10. McCamish M, Woollett G. Worldwide experience with biosimilar development. MAbs. 2011;3:209-217.
11. Hulse J, Cox C. In vitro functional testing methods for monoclonal antibody biosimilars. BioProcess Int. 2013;11:24-27.
12. Scott C. A decade of process development. BioProcess Int. 2012;10:72-78.
13. Aggarwal S. What's fueling the biotech engine-2012 to 2013. Nat Biotechnol. 2014;32:32-39.
14. Wang J, Chow S. On the regulatory approval pathway of biosimilar products. Pharmaceuticals. 2012;5:353-368.
15. Chugh PK, Roy V. Biosimilars: current scientific and regulatory considerations. Curr Clin Pharmacol. 2014;9:53-63.
16. FDA. Information for Consumers (Biosimilars). Available at: http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/Biosimilars/ucm241718.htm. Accessed December 22, 2014.
17. WHO Expert Committee on Biological Standardization. Guidelines on evaluation of similar biotherapeutic products (SBPs). Available at: http://www.who.int/biologicals/areas/biological_therapeutics/BIOTHERAPEUTICS_FOR_WEB_22APRIL2010.pdf. October, 2009. Accessed March 4, 2015.
18. PDMA. Recent Regulations of Biosimilar in Japan. Available at: http://www.pmda.go.jp/regulatory/file/english_presentation/biologics/B-E1arato.pdf.2011. Accessed December 22, 2014.
19. Health Canada. Fact Sheet: Subsequent Entry Biologics in Canada. Available at: http://www.hc-sc.gc.ca/dhp-mps/brgtherap/activit/fs-fi/fs-fi_seb-pbu_07-2006-eng.php. Accessed December 22, 2014.
20. ANVISA. Resolução RDC N° 55 de 16 de dezembro de 2010. Dispõe sobre o registro de produtos biológicos novos e produtos biológicos e dá outras providências. Available at: http://portal.anvisa.gov.br/wps/wcm/connect/73a029004ff7e91d980efe6d6e8afaaa/RDC+N%C2%BA+55, +DE+16+DE+DEZEMBRO+DE+2010.pdf?MOD=AJPERES December, 2010. Accessed December 18, 2014.
21. EMA/CHMP/437/04. Guideline on Similar Biological Medicinal Products. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003517.pdf. October, 2005. Accessed March 4, 2015.
22. Health Canada. Guidance for Sponsors: Information and Submission Requirements for Subsequent Entry Biologics (SEBs). Available at: http://www.hc-sc.gc.ca/dhp-mps/alt_formats/pdf/brgtherap/applic-demande/guides/seb-pbu/seb-pbu-2010-eng.pdf. March, 2010. Accessed March 4, 2015.
23. Consensus Information Paper 2013. What you need to know about Biosimilar Medicinal Products. European Commission. Available at: http://ec.europa.eu/enterprise/sectors/healthcare/files/docs/biosimilars_report_en.pdf. 2013. Accessed January 14, 2015.
24. FDA/Center for Drug Evaluation and Research (CDER)/Center for Biologics Evaluation and Research (CBER). Guidance for Industry: Quality Considerations in Demonstrating Biosimilarity to a Reference Protein Product (Draft Guidance). February, 2012.
25. FDA/Center for Drug Evaluation and Research (CDER)/Center for Biologics Evaluation and Research (CBER). Guidance for Industry: Scientific Considerations in Demonstrating Biosimilarity to a Reference Product (Draft guidance). February, 2012.
26. FDA/Center for Drug Evaluation and Research (CDER)/Center for Biologics Evaluation and Research (CBER). Guidance for Industry. Biosimilars: Questions and Answers Regarding Implementation of the Biologics Price Competition and Innovation Act of 2009 (Draft guidance). February, 2012.
27. Sandoz. FDA Accepts Sandoz Application for Biosimilar Filgrastim. Available at: http://www.sandoz.com/media_center/press_releases_news/global_news/2014_07_24_FDA_accepts_Sandoz_application_for_biosimilar_filgrastim.shtml. July, 2014. Accessed December 04, 2014.
28. Celltrion. Celltrion files for US FDA approval of Remsima®. Available at: http://www.celltrion.com/en/company/notice:view.asp?idx=456&code=ennews&intNowPage=1&menu_num=&align_year=all. August, 2014. Accessed December 04, 2014.
29. FDA/Center for Drug Evaluation and Research (CDER)/Center for Biologics Evaluation and Research (CBER). Guidance for Industry: Clinical Pharmacology Data to Support a Demonstration of Biosimilarity to a Reference Product (Draft guidance). May, 2014.
30. FDA/Center for Drug Evaluation and Research (CDER)/Center for Biologics Evaluation and Research (CBER). Guidance for Industry: Reference Product Exclusivity for Biological Products Filed Under Section 351(a) of the PHS Act (Draft guidance). August, 2014.
31. FDA. Purple Book: Lists of Licensed Biological Products with Reference Product Exclusivity and Biosimilarity or Interchangeability Evaluations. Available at: http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/Biosimilars/ucm411418.htm. September, 2014. Accessed January 8, 2015.
32. Tu EU, Wolfson JA. FDA Throws the (Purple) Book at Biosimilars-Purple v. Orange. Haynes and Boone's Newsroom. Available at: http://www.haynesboone.com/fda-purple-book-v-orange-book/. October, 2014. Accessed January 9, 2015.
33. Grabowski H, Long G, Mortimer R. Data exclusivity for biologics. Nat Rev Drug Discov. 2011;10:15-16.
34. Mann JS, Mahinka SP. Biosimilars: patent challenges and competitive effects. LMG Life Sci. 2014;September:33-36.
35. Reichertz P, Kim M. Sandoz and Celltrion Decline the Invitation to Dance: Biosimilars Challenge the Applicability of the BPCIA's Exchange Provisions Before Bringing Suit. Sheppard Mulin. Available at: http://www.fdalawblog.com/2014/11/articles/ip-and-technology-transactions/sandoz-and-celltrion-decline-the-invitation-to-dance-biosimilars-challenge-the-applicability-of-the-bpcias-exchange-provisions-before-bringing-suit/. November, 2014. Accessed February 10, 2015.
36. ® (filgrastim) Sandoz Inc., a Novartis company. Available at: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/OncologicDrugsAdvisoryCommittee/UCM428780.pdf. January, 2015. Accessed February 12, 2015.
37. Ledford H. First biosimilar drug set to enter US market. Nature. 2015;517:253-254.
38. Ebbers HC, Crow SA, Vulto AG, Schellekens H. Interchangeability, immunogenicity and biosimilars. Nat Biotechnol. 2012;30:1186-1190.
39. EMA/CHMP/BMWP/14327/2006. Guidelines on immunogenicity assessment of biotechnology-derived therapeutic proteins. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003946.pdf. April, 2008. Accessed March 4, 2015.
40. Tkaczuk KHR, Jacobs IA. Biosimilars in oncology: from development to clinical practice. Semin Oncol. 2014;41:S3-S12.
41. Rovira, J, Espin J, Garcia L, Olry de Labry A. The Impact of Biosimilars' Entry in the EU Market. Andalusian School of Public Health. Available at: http://citeseerx.ist.psu.edu/viewdoc/download?doi=10.1.1.357.2218&rep=rep1&type=pdf. January, 2011. Accessed January 15, 2015.
42. Kling J. Fresh from the biotech pipeline-2013. Nat Biotechnol. 2014;32:121-124.
43. Feagan BG, Choquette D, Ghosh S, Gladman DD, Ho V, Meibohm B, Zou G, Xu Z, Shankar G, Sealey DC, Russell AS. The challenge of indication extrapolation for infliximab biosimilars. Biologicals. 2014;42:177-183.
44. Weise M, Kurki P, Wolff-Holz E, Bielsky MC, Schneider CK. Biosimilars: the science of extrapolation. Blood. 2014;124:3191-3196.
45. Williams A. "No Clinically Meaningful Differences": The First Accepted Biosimilar Application Has Been Recommend for FDA Approval. Patents Doc. Available at: http://www.patentdocs.org/2015/01/no-clinically-meaningful-differences-the-first-accepted-biosimilar-application-has-been-recommend-fo.html. January, 2015. Accessed February 5, 2015.
46. Hospira. Developing Biosimilars. Available at: http://www.hospira.com/en/healthcare_trends/biologics/development_of_biosimilars/. Accessed December 18, 2014.
47. Scotté F, Launay-Vacher V, Rey JB. Colony stimulating factors (CSF) biosimilars. Progress? Target Oncol. 2012;7:S17-S24.
48. Weise M, Bielsky MC, De Smet K, Ehmann F, Ekman N, Narayanan G, Heim HK, Heinonen E, Ho K, Thorpe R, Vleminckx C, Wadhwa M, Schneider CK. Biosimilars-why terminology matters. Nat Biotechnol. 2011;29:690-693.
49. Subramanian R, Sheppard T, Rubin B, Kramer C. FDA's New Breakthrough Therapy Designation: What does it mean for Pricing and Market Access? OBR Green. Available at: http://obroncology.com/obrgreen/article/FDAs-New-Breakthrough-Therapy-Designation. September 2013. Accessed February 9, 2015.
50. FDA/Center for Drug Evaluation and Research (CDER)/Center for Biologics Evaluation and Research (CBER). Guidance for Industry. Expedited Programs for Serious Conditions-Drugs and Biologics. May, 2014.
51. Weise M, Bielsky MC, De Smet K, Ehmann F, Ekman N, Giezen TJ, Gravanis I, Heim HK, Heinonen E, Ho K, Moreau A, Narayanan G, Kruse NA, Reichmann G, Thorpe R, van Aerts L, Vleminckx C, Wadhwa M, Schneider CK. Biosimilars: what clinicians should know. Blood. 2012;120:5111-5117.
52. McCamish M, Woollett G. The state of the art in the development of biosimilars. Clin Pharmacol Ther. 2012;91:405-417.
53. McCamish M, Woollett G. The rise of the biosimilar. Expert Rev Clin Pharmacol. 2012;5:597-599.
54. Schiestl M, Stangler T, Torella C, Cepeljnik T, Toll H, Grau R. Acceptable changes in quality attributes of glycosylated biopharmaceuticals. Nat Biotechnol. 2011;29:310-312.
55. Ahmed I, Kaspar B, Sharma U. Biosimilars: impact of biologic product life cycle and European experience on the regulatory trajectory in the United States. Clin Ther. 2012;34:400-419.
56. Casadevall N, Nataf J, Viron B, Kolta A, Kiladjian JJ, Martin-Dupont P, Michaud P, Papo T, Ugo V, Teyssandier I, Varet B, Mayeux P. Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N Engl J Med. 2002;346:469-475.
57. Schellekens H. Immunologic mechanisms of EPO-associated pure red cell aplasia. Best Pract Res Clin Haematol. 2005;18:473-480.
58. Schellekens H. Biosimilar therapeutics-what do we need to consider? NDT Plus. 2009;2:i27-i36.
59. Shukla AA, Gottschalk U. Single-use disposable technologies for biopharmaceutical manufacturing. Trends Biotechnol. 2013;31:147-154.
60. País-Chanfrau JM, Zorrilla K, Chico E. The impact of disposables on project economics in a new antibody plant: a case study. BioPharm Int. 2009;22:62-74.
61. Russell J. Reducing uncertainty surrounding biosimilar production. Genetic Eng. News. 2012;32:26-30.
62. PharmaAsia. Rethinking Manufacturing: Toward a Single-Use Approach. PharmaAsia. Available at: http://www.pharmaasia.com/article/rethinking-manufacturing-toward-a-single-use-approach/10799. September, 2014. Accessed February 6, 2015.
63. FDA/Center for Biologics Evaluation and Research (CBER)/Center for Drug Evaluation and Research (CDER) Guidance: Demonstration of Comparability of Human Biological Products, Including Therapeutic Biotechnology-derived Products; 1996.
64. ICH. ICH Harmonised Tripartite Guideline. Comparability of Biotechnological/Biological Products Subject to Changes in their Manufacturing Process Q5E; 2005.
65. Federici M, Lubiniecki A, Manikwar P, Volkin DB. Analytical lessons learned from selected therapeutic protein drug comparability studies. Biologicals. 2013;41:131-147.
66. Scott C. Analytical methods for biologics. BioProcess Int. 2007;5:S35-S38.
67. Scott C. A decade of characterization. BioProcess Int. 2012;10:58-61.
68. Ridgway A, Ritter N, Schiestl M, Schreitmuller T. Biosimilar products. BioProcess International. Available at: http://www.bioprocessintl.com/manufacturing/biosimilars/biosimilar-products-347979/. November, 2013. Accessed August 1, 2014.
69. Galbraith D. Biosimilars awaken CROs. BioProcess Int. 2014;12:24-27.
70. Brinks V, Hawe A, Basmeleh AHH, Joachin-Rodriguez L, Haselberg R, Somsen GW, Jiskoot W, Schellekens H. Quality of original and biosimilar epoetin products. Pharm Res. 2011;28:386-393.
71. Xie H, Chakraborty A, Ahn J, Yu YQ, Dakshinamoorthy DP, Gilar M, Chen W, Skilton SJ, Mazzeo JR. Rapid comparison of a candidate biosimilar to an innovator monoclonal antibody with advanced liquid chromatography and mass spectrometry Technologies. mAbs. 2010;2:379-394.
72. Wei Z, Shacter E, Schenerman M, Dougherty J, McLeod LD. The role of higher-order structure in defining biopharmaceutical quality. BioProcess Int. 2011;9:58-66.
73. EMA/CHMP/BMWP/403543/2010. Guideline on Similar Biological Medicinal Products Containing Monoclonal Antibodies - Non-Clinical and Clinical Issues. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/06/WC500128686.pdf. December, 2012. Accessed March 4, 2015.
74. Jung SK, Lee KH, Jeon JW, Lee JW, Kwon BO, Kim YJ, Bae JS, Kim D, Lee SY, Chang SJ. Physicochemical characterization of Remsima®. mAbs. 2014;6:1163-1177.
75. Visser J, Feuerstein I, Stangler T, Schmiederer T, Fritsch C, Schiestl M. Physicochemical and functional comparability between the Proposed Biosimilar Rituximab GP2013 and originator Rituximab. BioDrugs. 2013;27:495-507.
76. Colbert A, Umble-Romero A, Prokopa S, Chow VF, Wonga T, DeSimone D, Zhou L, Pederson S. Bioanalytical strategy used in development of pharmacokinetic (PK) methods that support biosimilar programs. mAbs. 2014;6:1178-1189.
77. Abbas R, Jacobs IA, Li EC, Yin D. Considerations in the early development of biosimilar products [published online ahead of print January 6, 2015]. Drug Discov Today. doi: 10.1016/j.drudis.2014.12.017. In press.
78. van Meer PJ, Ebbers HC, Kooijman M, Wied CC, Silva-Lima B, Moors EH, Schellekens H. Contribution of animal studies to evaluate the similarity of biosimilars to reference products [published online ahead of print November 20, 2014]. Drug Discov Today. doi: 10.1016/j.drudis.2014.11.009. In press.
79. Brinks V, Jiskoot W, Schellekens H. Immunogenicity of therapeutic proteins: the use of animal models. Pharm Res. 2011;28:2379-2385.
80. Shivhare M, McCreath G. Practical considerations for DoE implementation in quality by design. BioProcess Int. 2010;8:22-30.
81. FDA. Pharmaceutical cGMPs for the 21st century-a risk-based approach. Available at:http://www.fda.gov/Drugs/DevelopmentApprovalProcess/Manufacturing/QuestionsandAnswersonCurrentGoodManufacturingPracticescGMPforDrugs/ucm137175.htm. Accessed December 23, 2014.
82. FDA/Center for Drug Evaluation and Research (CDER)/Center for Veterinary Medicine (CVM)/Office of Regulatory Affairs (ORA). Guidance for Industry. PAT-A Framework for Innovative Pharmaceutical Manufacturing and Quality Assurance; 2004.
83. ICH. ICH Harmonised Tripartite Guideline. Pharmaceutical Development Q8 (R2); 2009.
84. ICH. ICH Harmonised Tripartite Guideline. Development and Manufacture of Drug Substances (Chemical Entities and Biotechnological/Biological Entities) Q11; 2012.
85. ICH. ICH Harmonised Tripartite Guideline. Quality Risk Management Q9; 2005.
86. ICH. ICH Harmonised Tripartite Guideline. Pharmaceutical Quality Systems Q10; 2008.
87. Calcott P. Implementation of quality by design in vaccine development. BioProcess Int. 2013;11:12-17.
88. Girard FC. Process optimization of biosimilars production using NMR profiling. BioProcess Int. 2013;11:52-56.
89. FDA/Department of Health and Human Services. Submission of Chemistry, Manufacturing, and Controls Information in a New Drug Application Under the New Pharmaceutical Quality Assessment System (Docket No. 2005N-0262); 2005.
90. FDA/Department of Health and Human Services. Notice of Pilot Program for Submission of Quality Information for Biotechnology Products in the Office of Biotechnological Products (Docket number FDA-2008-N-03551); 2008.
91. Krummen L. Lessons Learned from Two Case Studies in the FDA QbD Biotech Pilot. Available at: http://c.ymcdn.com/sites/www.casss.org/resource/resmgr/CMC_Euro_Speaker_Slides/2013_CMCE_KrummenLynne.pdf. 2013. Accessed November 21, 2014.
92. FDA. FDA, EMA Announce Pilot for Parallel Assessment of Quality by Design Applications. Available at: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm247332.htm. March, 2011. Accessed December 4, 2014.
93. FDA. FDA-EMA Extends Pilot Program of the QbD Parallel-Assessment. Available at: http://www.fda.gov/Drugs/DrugSafety/ucm388009.htm. 2014. Accessed December 4, 2014.
94. Markets and Markets. Biosimilars Market Product [Recombinant Non-Glycosylated Proteins (Insulin, Filgrastim, Somatropin), Glycosylated (Monoclonal Antibodies, Erythropoietin), Peptides (Glucagon, Calcitonin)] & Application (Oncology, Blood Disorders)-Global Forecast to 2018. Available at: www.marketsandmarkets.com/Market-Reports/biosimilars-40.html?gclid=Cj0KEQiA8MSkBRCP5LaRlcOAusMBEiQAiqldkv9Iax6iWLafXqEs9ACqZuy8HkT3210UMyvzTA0zv2waAk9-8P8HAQ. November, 2013. Accessed December 18, 2014.
95. Cornes P. The economic pressures for biosimilar drug use in cancer medicine. Target Oncol. 2012;7:S57-S67.
96. Henry D, Taylor C. Pharmacoeconomics of cancer therapies: considerations with the introduction of biosimilars. Semin Oncol. 2014;41:S13-S20.
97. Mukherjee, S. RAND study: biosimilars could save US $44 billion in 10 years. BioPharma Dive. Available at:http://www.biopharmadive.com/news/rand-study-biosimilars-could-save-us-44-billion-in-10-years/328924/. November, 2014. Accessed December 18, 2014.
98. Lane EJ. Competition to J&J's Remicade looms in U.S. as biosimilar conquers new markets. Fierce Biotech. Available at: http://www.fiercebiotech.com/story/competition-jjs-remicade-looms-us-biosimilar-conquers-new-markets/2015-02-10?utm_campaign=+SocialMedia. February, 2015. Accessed February 11, 2015.
99. Warner JH. Arthritis Advisory Committee; Notice of Meeting. Federal Register. Available at: https://www.federalregister.gov/articles/2015/02/10/2015-02670/arthritis-advisory-committee-notice-of-meeting. February, 2015. Accessed February 11, 2015.
100. Mintz C. Biosimilars in emerging markets. BioProcess Online. Available at: http://www.bioprocessonline.com/doc/biosimilars-in-emerging-markets-0001. July, 2013. Accessed December 18, 2014.
101. Ministério da Saúde. Available at: http://bvsms.saude.gov.br/bvs/saudelegis/gm/2014/prt2531_12_11_2014.html. November, 2014. Accessed January 19, 2015.
102. Ministério da Saúde. Available at: http://pt.slideshare.net/MinSaude/medicamentos-biotecnolgicos-para-o-sus. June, 2013. Accessed December 23, 2014.
103. Guillon-Munos A, Daguet A, Watier H. Antibody biosimilars: fears or opportunities?: First LabEx MAb Improve industrial workshop, May 28, 2013; Tours, France. MAbs. 2014;6:805-809.
104. Reymond E. Dr Reddy's bets high on biosimilars. Indian drug maker Dr Reddy's is planning to launch one biosimilar every year in the next few years, according to Indian media reports. In-Pharma Technologist.com. Available at: http://www.in-pharmatechnologist.com/Drug-Delivery/Dr-Reddy-s-bets-high-on-biosimilars. August, 2007. Accessed December 18, 2014.
105. First World Pharma. Big Pharma's march on the biosimilars market gathers pace. First World Pharma. Available at: http://www.firstwordpharma.com/node/1056866#axzz3QzYbRX9j. February, 2013. Accessed February 6, 2015.